Entering text into the input field will update the search result below

Novartis says two children died after receiving gene therapy Zolgensma - STAT

Aug. 11, 2022 6:09 PM ETNovartis AG (NVS) StockBy: Jonathan Block, SA News Editor13 Comments

Futuristic Novartis Pavillon at campus

Santiaga/iStock Editorial via Getty Images

  • Two children have died after receiving Novartis' (NYSE:NVS) spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec), STAT reported.
  • The deaths occurred in Russia and Kazakhstan.
  • The children died about five to six weeks after the one-time infusion and between one and 10 days after corticosteroid tapering. The latter is done to maintain liver function.
  • In March, Novartis said Zolgensma was given to more than 1.8K patients globally.

Recommended For You

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG